Lead Optimization in Natural Product Chemical Space: A Methodological Model for Generative Design, Activity Prediction, Synthetic Feasibility, and Pharmacological Plausibility

Download PDF

Lead optimization in natural product chemical space requires a methodological logic that is broader than molecular generation, predicted potency, or structural novelty. Natural products and natural product-inspired scaffolds can provide stereochemical richness, scaffold diversity, three-dimensionality, dense functionalization, and biosynthetically patterned motifs, but these same features complicate chemical representation, predictive reliability, synthetic planning, and pharmacological interpretation. Disconnected computational workflows may overvalue a generated molecule because it is chemically valid, predicted to be active, apparently novel, or heuristically accessible, even when its route feasibility, mechanism coherence, exposure plausibility, or uncertainty profile remains unresolved. This article proposes an original methodological model for lead optimization in natural product chemical space by integrating chemical-space representation, constrained generative design, activity prediction, uncertainty and applicability assessment, synthetic feasibility analysis, pharmacological plausibility evaluation, cross-domain conflict resolution, iterative redesign, and candidate-state assignment. The model treats generated structures as candidate hypotheses rather than optimized leads, interprets predicted activity relative to evidence credibility, distinguishes synthetic accessibility from practical synthetic feasibility, and evaluates pharmacological plausibility through target relevance, mechanism coherence, selectivity, exposure compatibility, polypharmacology, and safety-related concerns. The principal contribution is a qualitative decision architecture that prevents any single computational layer from dominating progression decisions and assigns candidates to transparent states: experimental prioritization, targeted optimization, feasibility-constrained redesign, evidence-insufficient hold, or rejection from the current optimization path. The model is proposed as a methodological framework and is not presented as prospectively validated.